Skip to content
Fabrazyme(agalsidase beta)
Fabrazyme (agalsidase beta) is an enzyme pharmaceutical. Agalsidase beta was first approved as Fabrazyme on 2001-08-03. It is used to treat fabry disease in the USA. It has been approved in Europe to treat fabry disease.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Fabrazyme
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Agalsidase beta
Tradename
Proper name
Company
Number
Date
Products
Fabrazymeagalsidase betaGenzyme CorporationN-103979 RX2003-04-24
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
fabrazymeBiologic Licensing Application2021-03-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
fabry diseaseOrphanet_324D000795E75.21
Agency Specific
FDA
EMA
Expiration
Code
agalsidase beta, Fabrazyme, Genzyme Corporation
2028-03-11Orphan excl.
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AB: Enzymes for alimentary tract and metabolism
— A16AB04: Agalsidase beta
HCPCS
Code
Description
J0180
Injection, agalsidase beta, 1 mg
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Fabry diseaseD000795E75.212449524
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic renal insufficiencyD051436N18—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Irritable bowel syndromeD043183EFO_0000555K581———12
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hypertrophic cardiomyopathyD002312EFO_0000538I42.1————11
Lysosomal storage diseasesD016464————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAGALSIDASE BETA
INNagalsidase beta
Description
Fabrazyme (agalsidase beta) is an enzyme pharmaceutical. Agalsidase beta was first approved as Fabrazyme on 2001-08-03. It is used to treat fabry disease in the USA. It has been approved in Europe to treat fabry disease.
Classification
Enzyme
Drug classenzymes
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2108888
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDRZD65TSM9U (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Fabrazyme - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 829 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,482 adverse events reported
View more details